<- Go Home
Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Market Cap
GBP 11.7B
Volume
2.9M
Cash and Equivalents
GBP 619.0M
EBITDA
GBP 1.3B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
GBP 4.1B
Profit Margin
70.21%
52 Week High
GBP 16.56
52 Week Low
GBP 12.12
Dividend
2.81%
Price / Book Value
2.22
Price / Earnings
28.43
Price / Tangible Book Value
9.67
Enterprise Value
GBP 14.4B
Enterprise Value / EBITDA
10.44
Operating Income
GBP 886.0M
Return on Equity
7.86%
Return on Assets
5.44
Cash and Short Term Investments
GBP 619.0M
Debt
GBP 3.3B
Equity
GBP 5.3B
Revenue
GBP 5.8B
Unlevered FCF
GBP 655.8M
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium